At Celgene, our commitment to changing the course of human health extends to those living in developed nations and those living in developing parts of the world.
Celgene Global Health (CGH) is a dedicated R&D unit committed to discovering, developing and delivering novel drugs for Diseases of the Developing World (DDW). CGH is applying modern-day drug discovery efforts to help find treatments for malaria, tuberculosis and other diseases of the developing world.
CGH is screening our diverse chemical library against the pathogens for neglected diseases of the developing world.
Collaborating closely with disease experts from non- profit and academic institutions around the globe, CGH has utilized the diverse, drug-like properties of the company’s library of more than 400,000 compounds.
For several years, Celgene has worked with the Indiana University School of Medicine, Moi University Teaching and Referral Hospital in Eldoret, Kenya, and a consortium of North American academic health centers to deliver health services, conduct health research, and develop leaders in healthcare for both North America and Africa. The institutional collaborators are collectively named the Academic Model Providing Access to Healthcare (AMPATH).
Under the umbrella of the WeCare program, Celgene has become a corporate sponsor of World Child Cancer, whose mission is to improve cancer diagnosis, treatment and care for children across the developing world.